PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer

DOI: 10.1515/pp-2018-0114

Keywords: chemotherapy, platin-resistant ovarian cancer (rPROC), Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC), randomized phase III trial

Full-Text   Cite this paper   Add to My Lib

Abstract:

The French Oncologic and Gynecologic HIPEC – FROGHI Grou

Full-Text